Halia Therapeutics initiated treatment with HT-6184, a novel NLRP3 inhibitor, in an initial participant for its early-stage Phase 2a study aimed at addressing lower-risk types of myelodysplastic conditions.

Serious risk means a risk of a serious adverse drug experience.

Thrombin inhibitors are drugs that specifically target and inhibit thrombin, a key enzyme in blood clotting.

Guillain-Barré syndrome (GBS) is a rare disorder in which a person’s own immune system damages the nerve cells, causing muscle weakness and sometimes paralysis.

Agomab Initiates First-Stage Research Trial on AGMB-447 with Healthy Participants and Individuals Diagnosed with Idiopathic Pulmonary Fibrosis.

Protein amidation is the process through which a carboxyl group is converted into an amide group.

The development of STAT3 inhibitors will be increasingly valued in the future, and targeting the STAT3 signaling pathway has become a promising strategy for the treatment of various cancers.

The emergence of oligonucleotide drugs makes it possible to actively design drug sequences to target and silence disease genes.

At the 2023 ESMO_ASIA , the latest clinical results of Cadonilimab were presented, demonstrating its potential therapeutic effect on HCC and laying a solid foundation for the next wave of research.

FDA has accorded an expedited evaluation to the drug Tarlatamab, developed by Amgen, which is aimed at treating advanced-stage small cell lung cancer.

ROCK2 inhibitors are drugs targeting the ROCK2 enzyme, crucial in various cellular processes.

Maze Therapeutics has commenced the administration phase of its Phase 1 clinical evaluation of MZE829 to test subjects in good health.